Barclays’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History

Barclays’s Portfolio SCLN Stock Details SCLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-2,500	Closed	-$28K	–	6862
2016 Q1	$28K	Buy	+2,500	New	+$22.2K	﹤0.01%	5090
2014 Q3	–	Sell	-9,300	Closed	-$47K	–	7951
2014 Q2	$47K	Hold	9,300	–	–	﹤0.01%	6000
2014 Q1	$37K	Buy	+9,300	New	+$44.9K	﹤0.01%	6239
2013 Q3	–	Sell	-16,300	Closed	-$81K	–	7756
2013 Q2	$81K	Buy	+16,300	New	+$77.6K	﹤0.01%	5969

Barclays's SCLN Position: Q4 2017 in Review

Barclays sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q4 2017, closing a stake of 113,303 shares — an estimated $1.27M sold.

Barclays first reported a position in SCLN in Q2 2013 and held it in 18 quarters. The position peaked at $1.53M in Q4 2016. 0 funds tracked by Wall St. Rank hold SCLN as of Q4 2017.

Barclays reported no remaining Sciclone Pharmaceuticals Inc position as of Q4 2017 after selling out during the quarter.
Barclays sold 113,303 Sciclone Pharmaceuticals Inc shares in Q4 2017, an estimated $1.27M.
Barclays first reported a position in Sciclone Pharmaceuticals Inc in Q2 2013 and held it in 18 quarters.
Barclays's Sciclone Pharmaceuticals Inc position peaked at $1.53M in Q4 2016.
0 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q4 2017.

Based on Barclays's 13F filing for Q4 2017, filed 14 Feb 2018.